The German biotech company BioNTech expects to make a lot more money this year from the self-developed corona vaccine than it previously anticipated.
Of these, 450 million doses have now been delivered, and, according to the company, there are no indications that it needs to be adapted to also protect against new virus variants. For the whole of 2021, BioNTech, together with partner Pfizer, has orders for 1.8 billion doses of the vaccine worldwide, and orders for the following two years are also underway.
The first product ever brought to market by BioNTech is expected to generate EUR 12.4 billion in sales this year. Previously, the company counted on 9.8 billion euros in revenue thanks to the vaccine.
Recently, BioNTech, together with Pfizer, with whom it collaborates in large parts of the world, has invested a lot of money in expanding production capacity. Just under 3 billion vaccines can now be produced this year. Last weekend, the Germans also announced that they would make 1 billion doses per year with the Chinese Shanghai Fosun Pharmaceutical Group in China. Until now, Fosun was only BioNTech’s distribution partner.
In the first quarter, BioNTech sales amounted to more than 2 billion euros. A year earlier, that was 27.7 million euros. At the bottom of the line, the Germans were left with 1.1 billion euros. Last year there was a loss of 53.4 million euros in the first three months.